Abstract:Abstract Abstract 4419 Chronic myelogenous leukemia (CML) is characterized by the t(9;22) chromosomal translocation, which results in the generation of Bcr-Abl oncogene that encodes the chimeric Bcr-Abl protein with constitutive tyrosine kinase activity. Despite the great success of imatinib therapy in CML, not all patients, especially those in the accelerated or blastic phase, experience an optimal response to this drug or even to the more potent, second-generation TKIs. The emergence of resistance to TKIs has also become a significant problem implying that physiopathologically relevant cellular targets should be validated, such as NF-kappaB (NF-kB). Here we describe the activity of alantolactone, a small natural compound and see its effect on K562-sensitive (K562s, sensitive to imatinib) and K562-resistant (K562r, resistant to imatinib) cells. Results: Firstly, we used CCK-8 assay to determine the cell viability and found that K562s were inhibited up to 64.5% after 48 hours of incubation of 10uM concentration of alantolactone, Annexin V+ cells were up to 68% which were confirmed by morphological observation, and apoptosis-related proteins were activated during the treatment, suggesting its inducing-apoptosis ability. Secondly, incubation of alantolactone could inhibit NF-kB signaling activity, proved by inhibition of IkBa phosphorylation and blockade of nuclear translocation of p65, while the luciferase assay further revealed the inhibited transcription of NF-kB dependent reporter gene, which was confirmed by immunofluorescence staining. Of note, Bcr-Abl protein was specifically and rapidly down-regulated as early as 6 hours after 10uM of alantolactone treatment. And alantolactone-induced Bcr-Abl down-regulation could be partially reversed by the autophagy inhibitor chloroquine but not by the proteasome inhibitor MG132 or bortezomib, indicating that autophagy may contributes to Bcr-Abl reduction. Furthermore, similar concentration of alantolactone could also induce apoptosis in K562r cells and inhibited the growth of primary CD34+ leukemic cells from CML patients. Collectively, our results primarily demonstrated that alantolactone could induce apoptosis in CML cells, regardless of imatinib-sensitive or -resistant, by inhibiting NF-kB signaling and depleting Bcr/Abl through a unique mechanism. Alantolactone could be used as a probe for deciphering the mechanism of Bcr-Abl destruction and NF-kB inhibition, and this agent may be a promising candidate for treating CML patients. Disclosures: No relevant conflicts of interest to declare.

Hsp90 Inhibitor, BIIB021, Induces Apoptosis and Autophagy by Regulating Mtor-Ulk1 Pathway in Imatinib-Sensitive and -Resistant Chronic Myeloid Leukemia Cells.

Berbamine Exhibits Potent Antitumor Effects on Imatinib-Resistant CML Cells in Vitro and in Vivo

The Antiproliferation Effect of Berbamine on K562 Resistant Cells by Inhibiting NF‐κB Pathway

Biib021, An Hsp90 Inhibitor, Effectively Kills A Myelodysplastic Syndrome Cell Line Via The Activation Of Caspases And Inhibition Of Pi3k/Akt And Nf-Kappa B Pathway Proteins

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy.

The Novel Anticancer Agent JNJ-26854165 is Active in Chronic Myeloid Leukemic Cells with Unmutated BCR/ABL and T315I Mutant BCR/ABL Through Promoting Proteosomal Degradation of BCR/ABL Proteins

Bj-B11, A Novel Hsp90 Inhibitor, Induces Apoptosis in Human Chronic Myeloid Leukemia K562 Cells Through the Mitochondria-Dependent Pathway

Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.

Roles of Phosphorylated P210bcr/abl and Hsp90 Protein in Apoptosis Induced by Berbamine in K562 Cells.

Spautin-1, a Novel Autophagy Inhibitor, Enhances Imatinib-Induced Apoptosis in Chronic Myeloid Leukemia

Small-molecule Inhibitor Targeting the Hsp70-Bim Protein–protein Interaction in CML Cells Overcomes BCR-ABL-independent TKI Resistance

Tyrosine Kinase Inhibitor Thiotanib Targets Bcr-Abl and Induces Apoptosis and Autophagy in Human Chronic Myeloid Leukemia Cells.

BIIB021, an orally available and small-molecule inhibitor of HSP90, activates intrinsic apoptotic pathway in human cervical adenocarcinoma cell line (HeLa)

Inhibitory Effect of 4-Chlorobenzoyl Berbamine on Imatinib-Resistant K562 Cells in Vitro and in Vivo

Inhibition of IGF-IR Tyrosine Kinase Induces Apoptosis and Cell Cycle Arrest in Imatinib-Resistant Chronic Myeloid Leukaemia Cells.

Pseudolaric Acid B Induces Mitotic Arrest and Apoptosis in Both Imatinib-Sensitive and -Resistant Chronic Myeloid Leukaemia Cells.

Discovery of Berberine that Targetedly Induces Autophagic Degradation of both BCR-ABL and BCR-ABL T315I through Recruiting LRSAM1 for Overcoming Imatinib Resistance

The Hsp90 Inhibitor SNX-2112, Induces Apoptosis in Multidrug Resistant K562/ADR Cells Through Suppression of Akt/NF-κB and Disruption of Mitochondria-Dependent Pathways

Alantolactone Induces Apoptosis in Imatinib-Sensitive and -Resistant CML Cells by Inhibiting NF-KappaB Signaling and Degrading Bcr/Abl Protein

SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.

SHC004-221A1, a Novel Tyrosine Kinase, Potently Inhibits T315I Mutant BCR-ABL in Chronic Myeloid Leukemia